A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

This study is testing a combination of two drugs — simmitinib (a targeted therapy) and irinotecan (a chemotherapy) — as a second-line treatment for people with advanced esophageal squamous cell cancer whose disease progressed after standard first-line treatment. **You may be eligible if...** - You are between 18 and 70 years old - Your cancer has been confirmed by biopsy as esophageal squamous cell carcinoma - Your cancer progressed after one prior standard treatment (platinum + fluorouracil or taxane combined with immunotherapy) - You have at least one measurable tumor - Your physical performance is good (ECOG 0-1) - Your expected survival is more than 3 months - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have had more than one prior line of treatment for advanced disease - You have active uncontrolled brain metastases - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding - You have had prior treatment with simmitinib or irinotecan Talk to your doctor to see if this trial is right for you.